A HER2-targeted CAR-T cell combined with IL-15 expression, a recombinant lentivirus expression plasmid and a preparation method and application thereof
By constructing a recombinant lentiviral vector expressing HER2-CAR and IL-15 and transducing CD3+ T cells, the problems of insufficient killing activity and poor in vivo persistence of HER2-targeted CAR-T cells in the treatment of solid tumors were solved. This achieved efficient killing and long-term survival of CAR-T cells, optimized their biological characteristics, and made them suitable for the treatment of HER2-positive breast cancer.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- GUANGXI NORMAL UNIV
- Filing Date
- 2026-06-03
- Publication Date
- 2026-07-17
AI Technical Summary
HER2-targeting CAR-T cells have problems such as insufficient killing activity, poor persistence in vivo, and easy functional exhaustion in the treatment of solid tumors. There is an urgent need to construct efficient, stable, and safe HER2-targeting CAR-T cells that co-express IL-15 to optimize their function.
By constructing a recombinant lentiviral vector that can simultaneously express HER2-CAR and IL-15, CAR-T cells were transduced. The regulatory effect of IL-15 significantly enhanced in vitro killing activity, delayed cell exhaustion, and improved in vivo survival capacity. The preparation method included isolating CD3+ T cells, activating them, and transducing them with lentivirus to optimize the biological characteristics of CAR-T cells.
It significantly enhances the in vitro killing activity of CAR-T cells, prolongs their in vivo survival, optimizes their subset structure, reduces the expression of exhaustion markers, improves tumor suppression, and has good therapeutic safety, making it suitable for immunotherapy of solid tumors such as HER2-positive breast cancer.
Smart Images
Figure CN122405744A_ABST